Prof John Petrie

Tell us a little about yourself? 

My name is John Petrie and I am the Professor of Diabetes and Director of Clinical Trials at the University of Glasgow, UK. I have had a long-term interest in diabetes control and complications for example as Chief Investigator of the international JDRF-funded REMOVAL trial, we conducted the longest and largest trial of metformin in type 1 diabetes to date.

I am currently Chair of Leadership of Panel the Diabetes UK Clinical Study Groups and a member of the Diabetes UK Strategic Research Advisory Group.   In the past I was President of the European Group for the study of Insulin Resistance (2010-2015), a former Associate Editor of Diabetologia, and a current member of the ADA-EASD Technology Committee.  I was a leader in the early development of the successful Scottish Diabetes Research Network (SDRN, 2005-2010) and chaired the 2017 Scottish “SIGN 154” guideline on glucose-lowering therapy in type 2 diabetes and was a member of the LEADER trial Global Expert Panel.

Last year I completed six years as Chair of Board of Trustees of the Novo Nordisk UK Research Foundation (registered charity 1056410) and five years on the UK MRC/NIHR Efficacy and Mechanisms (EME) funding panel (the final two years as Deputy Chair).  At the international scale I have been on international research funding panels for type 1 diabetes including for JDRF, NHMRC Australia, and the Danish Diabetes Academy International Committee for Talent Development.

I am currently co-PI (with Dr Paresh Dandona, State University of New York) of a JDRF-funded trial of combined adjunct therapy in type 1 diabetes (TTT1).

I hold weekly diabetes clinics (types 1 and 2) at Stobhill Ambulatory Care Hospital, North Glasgow.

What’s the one thing you wish everyone know about diabetes? 

That as a result of research, innovation and listening to people affected by the condition. we have seen a large improvement in treatment in the last 10 years.